Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

CAARE · Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy

HORIZONStatus: SIGNED1 October 202430 September 2028EU funding €3,626,251Call HORIZON-MSCA-2023-DN-01

The Doctoral Network CAARE - “Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy” focuses on a rapidly emerging field in biopharmaceutical industry and a new class of molecules, the bionanoparticles. Bionanoparticles are currently used as conventional vaccines, mRNA vaccines or gene therapy. These new biopharmaceuticals will satisfy an urgent medical need as they might extend the curability of to-date non-curable diseases and offer treatment for rare diseases. However, the impact of the manufacturing process for such therapies on the final product quality and consequently on product efficacy and patient safety is still not fully understood. There also is a lack of specifically trained personnel in the field of bionanoparticles.In CAARE we will develop new and intensified downstream processes and analytical tools, which are essential to obtain a pure therapeutic product and to ensure the efficacy and safety of the therapy. acib GmbH (AT), Karlsruhe Institute of Technology, University of Hamburg and University of Erlangen (all DE), Institute of Experimental Biology and Technology (PT), Leiden University Medical Centre (NL), and Icosagen (EE), seven associated industry partners, two associated universities and one regulatory agency have formed a consortium to train 14 doctoral candidates with beyond state-of-the art bioprocess and analytical skills directed for bionanoparticle purification. Latest technology of process control and monitoring for advanced bionanoparticle processing, downstream process development and particle characterization of bionanoparticles will be taught. The appropriate skills to communicate the research outcome to the scientific community and to the general public are included in the training program. We will establish a new training creating a generation of scientists that can contribute to the establishment of technologies/methodologies in a rapidly emerging field in biopharmaceutical manufacturing.

Consortium · 17 organisations

coordinator

ACIB GMBH

AT · €810,994

participant

ACADEMISCH ZIEKENHUIS LEIDEN

NL · €548,741

participant

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG

DE · €260,539

associatedPartner

Refeyn GmbH

DE

associatedPartner

Phoenestra GmbH

AT

associatedPartner

VIRALGEN VECTOR CORE, S.L.

ES

associatedPartner

ROCHE DIAGNOSTICS GMBH

DE

associatedPartner

AGES - OSTERREICHISCHE AGENTUR FUR GESUNDHEIT UND ERNAHRUNGSSICHERHEIT GMBH

AT

participant

UNIVERSITY OF HAMBURG

DE · €521,078

associatedPartner

UNIVERSIDADE NOVA DE LISBOA

PT

associatedPartner

GENIBET - BIOPHARMACEUTICALS SA

PT

participant

KARLSRUHER INSTITUT FUER TECHNOLOGIE

DE · €521,078

participant

ICOSAGEN CELL FACTORY OU

EE · €477,014

associatedPartner

SimVantage GmbH

AT

associatedPartner

UNIVERSITAET FUER BODENKULTUR WIEN

AT

associatedPartner

Alfawassermann BV

NL

participant

INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA

PT · €486,806

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.